NASDAQ: KURA · Life Sciences · 3 alerts · CIK 1422143
Share price
$7.09Close, Nov 16
Market cap
$651M
Shares outstanding
91.88MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kura Oncology, Inc. filings on SEC EDGAR ↗
Kura Oncology President and CEO Troy Edward Wilson Buys $1.5M of Stock
Troy Edward Wilson, President and CEO, bought 200,000 shares of Kura Oncology, Inc. at $7.42 to $7.63 a share (average $7.52) in 2 transactions, worth $1.5M in total between Nov 13, 2026 and Nov 16, 2026. Shares held after the trade: 635,456 (+18.9%).
Kura Oncology reported total revenue of $22.8 million for Q3 2026, driven by the introduction of $13.9 million in product revenue. Despite this, the company recorded a net loss of $70.2 million for the quarter and $211.9 million for the first nine months of 2026, with total stockholders' equity declining significantly to $18.0 million from $174.1 million at year-end 2025.
Kura Oncology reported Q3 2026 financial results, highlighted by $13.9 million in net product revenue for KOMZIFTI, representing 53% sequential growth. The company reached FDA alignment on a registrational study design for darlifarnib in salivary gland cancer and secured a strategic financing agreement with Oberland Capital for up to $300 million.
Term
Q3 2026
“KOMZIFTI delivered strong commercial performance this quarter, with 53% sequential revenue growth, a 30% increase in new patients starts, and continued majority share of new patient starts. We believe these results demonstrate the growing commercial potential of KOMZIFTI and provide a strong foundation as we advance ziftomenib into the substantially larger frontline AML opportunity.”
Troy Wilson, Ph.D., J.D., President and Chief Executive Officer